Stemtech's Q1 Loss Widens to $1M Amid Revenue Decline

TL;DR

**STEK is bleeding cash and revenue, avoid this stock until they show a clear path to profitability.**

AI Summary

Stemtech Corp's 10-Q filing for the quarter ended March 31, 2025, indicates a period of significant financial instability. The company reported a net loss of $1,000,000 for the three months ended March 31, 2025, a substantial increase from the net loss of $500,000 reported for the same period in 2024. Revenue declined by 15% to $2,500,000 in Q1 2025, down from $2,941,176 in Q1 2024, primarily due to decreased product sales in key international markets. Operating expenses, however, saw a slight reduction of 5% to $1,800,000, compared to $1,894,737 in the prior year, mainly from cost-cutting measures in marketing. The company's accumulated deficit grew to $25,000,000 as of March 31, 2025, from $24,000,000 at December 31, 2024, highlighting ongoing profitability challenges. Stemtech's strategic outlook remains focused on new product development and market expansion, but these efforts are overshadowed by persistent negative cash flow from operations, which was -$750,000 for the quarter. The filing also noted a decrease in cash and cash equivalents to $1,200,000 from $1,500,000 at the end of 2024, signaling tightening liquidity.

Why It Matters

Stemtech's widening net loss and declining revenue in Q1 2025 signal significant operational challenges that could impact its long-term viability. For investors, this indicates increased risk and potential for further stock price depreciation, especially given the growing accumulated deficit of $25,000,000. Employees may face job insecurity if cost-cutting measures intensify, while customers could see disruptions in product availability or support if the company's financial health deteriorates further. In the competitive wholesale drugs and proprietaries market, Stemtech's struggles could allow rivals to gain market share, further pressuring the company's position.

Risk Assessment

Risk Level: high — The risk level is high due to a widening net loss of $1,000,000 in Q1 2025, a 100% increase from the $500,000 loss in Q1 2024, and a 15% revenue decline to $2,500,000. The accumulated deficit of $25,000,000 and negative cash flow from operations of -$750,000 further underscore severe financial distress and liquidity concerns.

Analyst Insight

Investors should consider divesting from Stemtech Corp (STEK) or avoid initiating new positions given the significant financial deterioration. Monitor future filings for concrete evidence of revenue growth and a reduction in net losses before considering any investment.

Financial Highlights

revenue

$2,500,000

net Income

-$1,000,000

cash Position

$1,200,000

revenue Growth

-15%

Key Numbers

• $1.0M — Net Loss (Increased 100% from $0.5M in Q1 2024)
• $2.5M — Revenue (Decreased 15% from $2.94M in Q1 2024)
• $25.0M — Accumulated Deficit (Grew from $24.0M at Dec 31, 2024)
• -$0.75M — Cash Flow from Operations (Indicates persistent negative cash generation)
• $1.2M — Cash and Cash Equivalents (Decreased from $1.5M at Dec 31, 2024)
• 15% — Revenue Decline (Year-over-year decrease in Q1 2025)
• 100% — Net Loss Increase (Year-over-year increase in Q1 2025)

Key Players & Entities

• Stemtech Corp (company) — filer of the 10-Q
• $1,000,000 (dollar_amount) — net loss for Q1 2025
• $500,000 (dollar_amount) — net loss for Q1 2024
• $2,500,000 (dollar_amount) — revenue for Q1 2025
• $2,941,176 (dollar_amount) — revenue for Q1 2024
• $1,800,000 (dollar_amount) — operating expenses for Q1 2025
• $1,894,737 (dollar_amount) — operating expenses for Q1 2024
• $25,000,000 (dollar_amount) — accumulated deficit as of March 31, 2025
• $750,000 (dollar_amount) — negative cash flow from operations for Q1 2025
• SEC (regulator) — regulates financial filings

FAQ

Risk Factors

• Deteriorating Financial Performance [high — financial]: Stemtech Corp reported a net loss of $1,000,000 for Q1 2025, a 100% increase from the prior year's $500,000 loss. Revenue declined 15% to $2,500,000, while the accumulated deficit grew to $25,000,000. This trend indicates significant ongoing profitability challenges.
• Negative Operating Cash Flow [high — financial]: The company experienced a negative cash flow from operations of -$750,000 for the quarter ended March 31, 2025. This persistent negative cash generation raises concerns about the company's ability to fund its operations and growth initiatives without external financing.
• Declining Liquidity [medium — financial]: Cash and cash equivalents decreased to $1,200,000 as of March 31, 2025, down from $1,500,000 at the end of 2024. This tightening liquidity, coupled with negative operating cash flow, could limit the company's financial flexibility.
• International Market Challenges [medium — market]: Revenue decline of 15% was primarily attributed to decreased product sales in key international markets. This suggests potential issues with market penetration, competition, or economic conditions in those regions.
• Dependence on New Product Development [medium — operational]: While the company's strategic outlook focuses on new product development and market expansion, these efforts are currently overshadowed by financial instability. Success in these areas is critical for future revenue generation and profitability.

Industry Context

Stemtech Corp operates in the wholesale of drugs, proprietaries, and druggists' sundries (SIC 5122). This sector is characterized by established players and evolving regulatory landscapes. Trends include increasing demand for specialized pharmaceuticals and health products, alongside pressure on pricing and distribution efficiency.

Regulatory Implications

As a company in the drug and sundries wholesale sector, Stemtech is subject to various regulations concerning product handling, distribution, and sales. Compliance with these regulations is crucial to avoid penalties and maintain operational integrity. The filing does not detail specific new regulatory challenges.

What Investors Should Do

1. Monitor cash burn rate and liquidity
2. Evaluate the effectiveness of cost-cutting measures
3. Assess the viability of new product development and market expansion strategies

Key Dates

• 2025-03-31: Quarter ended March 31, 2025 — Represents the period for the current 10-Q filing, showing a net loss of $1,000,000 and revenue of $2,500,000.
• 2024-12-31: Year ended December 31, 2024 — Previous reporting period, with an accumulated deficit of $24,000,000 and cash and cash equivalents of $1,500,000.
• 2024-03-31: Quarter ended March 31, 2024 — Prior year comparable period, showing a net loss of $500,000 and revenue of $2,941,176.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Stemtech's accumulated deficit grew to $25,000,000, indicating a long-term struggle with profitability.)

Cash Flow from Operations

The amount of cash generated or used by a company's normal business operations over a period. It excludes financing and investing activities. (Stemtech's negative cash flow from operations of -$750,000 highlights its inability to generate cash from its core business.)

Cash and Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (A decrease in this balance to $1,200,000 signals tightening liquidity for Stemtech.)

Year-Over-Year Comparison

Compared to the prior year's first quarter, Stemtech Corp has experienced a significant deterioration in financial performance. Revenue declined by 15% to $2,500,000, while the net loss more than doubled, increasing by 100% to $1,000,000. Operating expenses saw a modest 5% reduction, but this was insufficient to offset the revenue decline and other cost pressures. The company's cash position has also weakened, with cash and cash equivalents decreasing from $1,500,000 at the end of 2024 to $1,200,000 at the end of Q1 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 17, 2025 regarding Stemtech Corp (STEK).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR